Trials / Completed
CompletedNCT06438172
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1803-3 | Take it once daily for 8 weeks orally. |
| DRUG | RLD2001-1 | Take it once daily for 8 weeks orally. |
| DRUG | HPP2003-3 | Placebo drug. Take it once daily for 8 weeks orally. |
| DRUG | HPP2002-1 | Placebo drug. Take it once daily for 8 weeks orally. |
Timeline
- Start date
- 2024-03-25
- Primary completion
- 2024-12-02
- Completion
- 2024-12-02
- First posted
- 2024-05-31
- Last updated
- 2025-02-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06438172. Inclusion in this directory is not an endorsement.